Shanghai Model Organisms Center, Inc. (SHA:688265)
42.66
-0.44 (-1.02%)
Apr 21, 2026, 3:00 PM CST
SHA:688265 Revenue
In the year 2025, Shanghai Model Organisms Center had annual revenue of 421.26M CNY with 10.50% growth. Shanghai Model Organisms Center had revenue of 118.56M in the quarter ending December 31, 2025, with 1.86% growth.
Revenue
421.26M
Revenue Growth
+10.50%
P/S Ratio
7.66
Revenue / Employee
576.28K
Employees
749
Market Cap
3.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 421.26M | 40.02M | 10.50% |
| Dec 31, 2024 | 381.24M | 14.69M | 4.01% |
| Dec 31, 2023 | 366.55M | 63.58M | 20.99% |
| Dec 31, 2022 | 302.97M | 27.70M | 10.06% |
| Dec 31, 2021 | 275.27M | 79.08M | 40.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beijing Kawin Technology Share-Holding | 1.15B |
| Guangdong VTR Bio-Tech | 830.87M |
| Zhejiang Shouxiangu Pharmaceutical | 642.66M |
| Cabio Biotech (Wuhan) | 574.88M |
| Suzhou Fushilai Pharmaceutical | 439.57M |
| Yantai Zhenghai Biotechnology | 347.75M |
| Jiangsu Sihuan Bioengineering | 344.38M |
| Shanghai Shen Lian Biomedical | 288.27M |